Mirion’s third quarter results were received positively by the market, reflecting strong momentum in its core nuclear power business and improved profitability across both its Nuclear and Safety and Medical segments. Management attributed the quarter’s performance to robust organic growth in the nuclear end market, accelerated orders for small modular reactors (SMRs), and continued margin expansion through procurement initiatives. CEO Tom Logan emphasized that approximately 80% of Mirion’s nuclear revenue derives from the installed base of operating reactors, providing a stable foundation for growth. Logan also highlighted the company’s efforts to strengthen its position through recent acquisitions and operational improvements, which fueled both top-line growth and margin gains.

Is now the time to buy MIR? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Mirion’s Q3 Earnings Call

• Andy Kaplowitz (Citigroup) asked whether Mirion’s nuclear backlog could materially accelerate given recent activity. CEO Thomas Logan said backlog growth will likely continue as capacity factors rise and new builds advance, but timing is hard to predict.
• Joseph Ritchie (Goldman Sachs) inquired about the likelihood of securing the $175 million remaining in Mirion’s large project pipeline this year. CFO Brian Schopfer expressed confidence but noted that government-related projects may spill into 2026 due to funding dynamics.
• Robert Mason (Baird) questioned how new large order awards would affect Mirion’s next-12-month revenue coverage. Schopfer said Q4 is typically a strong booking quarter and that new contracts will be recognized over multiple years, not all at once.
• Tomohiko Sano (JPMorgan) asked how Mirion is managing supply chain and talent needs for large projects. Logan responded that recent acquisitions have strengthened the team and that supply chain risk is managed by securing materials and diversifying suppliers in advance.
• Yuan Zhi (B. Riley) sought details on the U.S. health care climate’s impact on medical sales. Logan explained that Medicaid cuts and industry uncertainty have delayed capital spending, but demand fundamentals remain intact and should normalize over time.

Catalysts in Upcoming Quarters

Looking ahead, our team will be tracking (1) the pace of new nuclear project awards and backlog growth, especially for SMRs and utility-scale builds, (2) the successful integration and operational impact of Paragon and Certrec acquisitions, and (3) recovery in the medical RTQA segment as U.S. health care funding pressures ease. Progress in margin expansion and procurement initiatives will also be key to watch.

Mirion currently trades at $29.95, up from $25.20 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free for active Edge members).

High-Quality Stocks for All Market Conditions

Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.